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Summary
 
Dendritic cells initiate immune responses by ferrying antigen from the tissues to the lymphoid
organs for presentation to lymphocytes. Little is known about the molecular mechanisms un-
derlying this migratory behavior. We have identified a chemokine receptor which appears to
be selectively expressed in human dendritic cells derived from CD34
 
1
 
 cord blood precursors,
but not in dendritic cells derived from peripheral blood monocytes. When stably expressed as a
recombinant protein in a variety of host cell backgrounds, the receptor shows a strong interac-
tion with only one chemokine among 25 tested: the recently reported CC chemokine mac-
rophage inflammatory protein 3
 
a
 
. Thus, we have designated this receptor as the CC chemo-
kine receptor 6. The cloning and characterization of a dendritic cell CC chemokine receptor
suggests a role for chemokines in the control of the migration of dendritic cells and the regula-
tion of dendritic cell function in immunity and infection.
 
D
 
endritic cells (DCs)
 
1
 
 are central to antigen-specific im-
munity in vertebrates. They act in vivo as immune
potentiating cells, sampling the antigenic environment and
presenting those antigens to effector lymphocytes (for reviews
see references 1 and 2). DCs are found at many sites in the
body, particularly at or near surface areas where antigen
contact is likely, and in the lymphoid organs where they
form close associations with T cells. Migration is an integral
part of DC function; precursor cells must migrate from the
bone marrow to resident sites in the tissue. After exposure
to antigen or inflammatory stimuli, many DCs migrate from
their resident sites to the secondary lymphoid organs (1–4).
Much of how DCs achieve their migratory functions remains
a mystery. Recent attention has focused on the chemokine
system, a multipartite superfamily of chemoattractant cyto-
kines that induce the directed migration of leukocytes and
other cells, and on the superfamily of G protein–coupled,
seven transmembrane receptor proteins through which che-
mokines act (for reviews see references 5–8). Chemokines are
involved not only in immune cell trafficking and inflamma-
tion, but are also central to infectious disease processes. For
example, certain chemokines have been shown to be en-
dogenous inhibitors of HIV-1 entry (9), and some chemokine
receptors are ‘cofactors’ or ‘second receptors’ for HIV binding
and fusion with target cells (10–15).
The understanding of how chemokines might regulate
the migration of DCs is still rather sparse, though a few re-
ports clearly demonstrate that certain CC chemokines are
indeed chemoattractants for some types of DC in vitro (16,
17). It has been also demonstrated that HIV-1 can infect
DCs in vitro through interactions with CC chemokine re-
ceptor (CCR)5, CXC chemokine receptor (CXCR)4, and
probably another chemokine receptor (18). To address some
of the questions surrounding the control of DC function at
the molecular level, we sought to identify new elements of the
chemokine system in these cells. Here, we report on the isola-
tion of a new chemokine receptor, CCR6, which is highly
expressed in CD34
 
1
 
 cell-derived DCs, but not in mono-
 
1
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cyte-derived DCs, and its interaction with a recently de-
scribed CC chemokine, macrophage inflammatory protein
(MIP)-3
 
a
 
 (19).
 
Materials and Methods
 
PCR Screening of cDNA Libraries.
 
cDNA plasmid libraries from
DCs, eosinophils, and T cells were used as templates in PCR re-
actions as follows: 50 
 
m
 
l total volume in 0.2-ml tubes with 5 
 
m
 
M
degenerate primers second intracellular loop (IC2) sense (5
 
9
 
GATCGNTAGCTNGCNATNGTNCA T/C GC) and trans-
membrane (TM)7 antisense (5
 
9
 
 GCATANATNANNGG G/A T
C/T NAN G/A CAGCAGTG) in buffer containing 20 mM
NH
 
4
 
S0
 
4
 
, 75 mM Tris HCl, pH 9.0, at 25
 
8
 
C, 0.01% Tween 20, 2
mM MgCl
 
2
 
, 200 mM deoxynucleotide triphosphates and 2.5
units Taq DNA polymerase (ABT, London, UK). “Touchdown”
PCR was performed as follows: 15 cycles of 94
 
8
 
C for 1 min, 65–
50
 
8
 
C annealing for 1 min decreasing by 1
 
8
 
 per cycle, and at 72
 
8
 
C
for 2 min followed by 20 cycles of 94
 
8
 
C for 30 s, 50
 
8
 
C for 1 min,
and 72
 
8
 
C for 2 min. PCR products (550 bp) were purified after
agarose gel electrophoresis by absorption to glass beads (Qiaex II;
Qiagen GmbH, Hilden, Germany) and cloned via Taq DNA
polymerase A overhangs into the T-tailed vector pTAg1 (R&D
Sys. Inc., Abingdon, UK). Recombinant plasmids were identified
by colony PCR and restriction mapping, and double-strand se-
quencing was performed using flanking M13 and T7 primers.
Full-length BN-1 cDNA sequence was obtained by PCR ampli-
fication using BN-1–specific oligonucleotides and M13 forward
and reverse primers to PCR amplify BN-1 sequences from hu-
man DC cDNA libraries constructed in the cloning vector
pSPORT (GIBCO BRL, Gaithersburg, MD). In addition, radio-
labeled probes generated from the PCR products were used to
isolate full-length BN-1 clones by colony hybridization.
 
Analysis of Gene Expression Distribution.
 
Northern blot analy-
sis was performed using a multiple tissue Northern blot purchased
from Clontech (Palo Alto, CA). Where limited amounts of mes-
senger RNA (mRNA) precluded direct Northern analysis, ex-
pression was assessed on Southern blots of cDNA libraries. Li-
braries were constructed from polyA
 
1
 
 RNA selected with
oligotex beads (Qiagen, Chatsworth, CA). 2 
 
m
 
g of mRNA was
primed by oligo dT (Superscript cDNA synthesis kit; GIBCO
BRL), and the quality of the resulting cDNA was evaluated by
three criteria: (
 
a
 
) a size range of cDNA from the first strand syn-
thesis ranging from 
 
.
 
0.5 to 5 kb on alkaline gel analysis, (
 
b
 
) inde-
pendent clones numbering greater than 10
 
6
 
/100 ng of unampli-
fied cDNA, and (
 
c
 
) a high proportion of full-length clones with
low levels of genomic or ribosomal RNA contamination (
 
,
 
5%),
as assessed by random sequence analysis of each library. For
Southern analysis, large scale plasmid DNA preparations of ampli-
fied libraries were done using a Giga prep (Qiagen). 5 
 
m
 
g from
the primary amplified cDNA library was digested with NotI and
SalI (Boehringer Mannheim, Indianapolis, IN) to release the in-
serts, run on a 1% agarose gel, and transferred to a nylon mem-
brane (Schleicher & Schuell, Keene, NH). Blots were probed
with a 
 
32
 
P-labeled BN-1 cDNA fragment under high stringency
hybridization and wash conditions. The resultant hybridization
patterns reflect the different sized cDNA fragments in the libraries
and their relative abundance. To confirm that the restricted distri-
bution was reflective of unamplified mRNA, semiquantitiative
PCR was performed on total RNA isolated directly from mono-
cytes, monocyte-derived DCs, and CD34
 
1
 
 cell-derived DCs. The
amplification pattern mirrored the hybridization patterns seen in
the library Southern blots.
 
Chromosomal Localization.
 
Genomic DNA (400 ng) from a
panel of 20 human–rodent somatic cell hybrids cell lines (Bios-
map; BIOS Labs., New Haven, CT) was used as a template in a
50-
 
m
 
l PCR reaction. The primer pairs were: BN1, 5
 
9
 
 GACCG-
GTACATCGCCATTGTACAGGC; BN2, 5
 
9
 
 CTGAACTTC-
TGCCCAATAAAAGCGTAG; BN3, 5
 
9
 
 GTACAAGTCCT-
CAGGCTTCTCCTG; and BN4, 5
 
9
 
 TGCATAACATCTAT-
GAGTATGTTTCAC. Human TNF-
 
a
 
 promoter primers TNF1:
5
 
9
 
 CAAACACAGGCCTCAGGACTC and TNF2: 5
 
9
 
 AGGGAG-
CGTCTGCTGGCTG were a gift of Dominic Kwiatkowski.
Genomic DNA from a panel of 16 somatic cell hybrids contain-
ing deletions and translocations of human chromosome 6 were a
gift of Dr. J.M. Boyle (Paterson Institute, Manchester, UK). Ge-
nomic DNAs of the radiation hybrid mapping panel Genebridge
4 were obtained from the Medical Research Council HGMP
Resource Centre (Cambridge, UK).
 
Receptor–Ligand Binding and Signaling Analyses.
 
Full-length BN-1
expression constructs were first made in pcDNA3 (Invitrogen,
San Diego, CA) and used to generated stable transfectants in hu-
man embryonic kidney 293 (HEK293) cells as described (20). To
control for levels of cell-surface expression of the receptor, subse-
quent constructs were made in which the M2 “Flag” epitope was
attached to the NH
 
2
 
-terminal portion of the receptor. Anti-M2
antibody was then used to detect cell-surface BN-1–encoded
polypeptide and to sort the highest expressing cells for stable
propagation. Intracellular calcium signaling analyses were per-
formed as described (21). Equlibrium binding was done using a
standard filtration protocol using 10
 
6
 
 cells incubated with 0.1 nM
[
 
125
 
I]MIP-3
 
a
 
 (custom labeled by Amersham, Arlington Heights,
IL) in the presence increasing amounts of unlabeled MIP-3
 
a
 
competitor. Reactions were incubated for 2 h at 22
 
8
 
C before be-
ing aspirated onto GF/C filters, washed, and measured by scintil-
lation counting. Data were analyzed using IgorPro software
(WaveMetrics, Lake Oswego, Oswego, OR).
 
Results
 
Cloning of Novel Chemokine Receptor Candidate cDNAs.
 
Degenerate reverse transcription PCR was used to identify
novel chemokine receptor-like sequences from several cell
types: monocytes, cultured T cells, eosinophils, and DCs. A
combination of primer pairs was used representing homol-
ogous regions within the family of known chemokine re-
ceptors and other seven transmembrane–spanning receptors
associated with cell motility. Primer pairs from regions en-
coding TM2 and TM7, as well as the IC2, were used on
substrate mRNA or cDNA from the cells listed above. Of
these, primer pair IC2 sense and TM7 antisense generated
from DCs, and to a lesser extent eosinophils, a 550-bp
PCR product whose sequence was at that time not present
in any of the available databases. The 550-bp cDNA repre-
senting the IC2–TM7 segment were then used to isolate
from a DC library a larger cDNA clone, designated ‘Bar-
ney’ or BN-1, encoding the entire presumptive open reading
frame (ORF) of a novel chemokine receptor-like protein.
The predicted protein sequence encoded by the BN-1
ORF is shown in Fig. 1, aligned with human CXCR2
(formerly known as IL-8RB) and human CCR4. During
further characterization of the function of the BN-1 pro-
tein, the same sequence was subsequently deposited as an
“orphan” TM7 receptor in the EMBL/GenBank/DDBJ 
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database as accession No. U68030, and was reported as a
potential chemokine-like orphan receptor sequence of un-
known function (22, 23). Multiple sequence alignment of
the protein encoded by BN-1 with other human chemo-
kine receptor sequences showed amino acid identity with
CXCR1 and CXCR2 of 
 
z
 
38%, but this is only slightly
more identity than to the closest human CC chemokine
receptor (CCR4, 
 
z
 
36%). The sequence alignment of Fig.
1 shows that parts of the BN-1–encoded ORF share exten-
sive homology with CXC receptors, but not CC receptors
(e.g., within TM3), whereas other parts of the BN-1 ORF
show closer homology to CCR4 (e.g., the intracellular
TM3–TM4 loop). Phylogenetic depictions of the evolu-
tionary relatedness of the various chemokine receptors show
BN-1 to be on a branch containing CXCR1, CXCR2,
and CXCR4, and distinct from the branch containing the
previously described human CC chemokine receptors
CCR1–CCR5 (not shown).
 
Chromosomal Localization of the BN-1 Gene.
 
We analyzed a
panel of human–rodent somatic cell hybrids to ascertain the
location of the human BN-1 gene. PCR using two pairs of
BN-1–specific oligonucleotides consistently yielded a PCR
product in only those hybrids containing human chromo-
some 6 (Fig. 2 
 
A
 
). Positive controls using PCR primers
against a known human chromosome 6 gene, human TNF,
confirmed the hybrid cell line karyotyping (Fig. 2 
 
B
 
), and
localization of BN-1 on human chromosome 6 was con-
firmed by PCR typing of chromosome 6 deletion and
translocation hybrids (not shown). We next used a radia-
tion hybrid panel (Fig. 2 legend) to unambiguously localize
the BN-1 gene to 6q26-27, consistent with the fluorescent
in situ hybridization analysis of Liao, et al. (23). This con-
stitutes a new locus for chemokine receptors; the CC
chemokine receptors CCR1–CCR5 are closely linked on
chromosome 3p21, the CXC receptors CXCR1 and
CXCR2 map to chromosome 2q35, and CXCR4 maps to
chromosome 2q21.
 
Distribution of BN-1 Message.
 
Various direct and indirect
approaches were used to assess the distribution of BN-1
mRNA. A Northern blot containing mRNA from a vari-
ety of organs and tissues showed an 
 
z
 
3.5-kb message pre-
dominantly in spleen, and to a lesser extent in thymus, testis,
small intestine, and peripheral blood (Fig. 3 
 
A
 
, 
 
top left
 
). In
addition, the spleen showed two smaller transcripts of 
 
z
 
2.7
and 1.7 kb. mRNAs from various lymphoid and hemato-
poietic cell lines (TF-1, Jurkat, MRC5, JY, and U937; Fig 3
 
A
 
, 
 
top right
 
) were negative for BN-1 expression. For cell
Figure 1. Sequence homology of the BN-1–coding region with other
chemokine receptors. The deduced 374–amino acid sequence encoded by
the BN-1 cDNA was compared to other human and viral chemokine re-
ceptors using the multiple sequence alignment program Pileup of the Wis-
consin EGCG DNA analysis software package. Shown here is the BN-1
amino acid sequence aligned with the human CXCR2 and CCR4. The
positions of the hydrophobic membrane spanning regions TM1–TM7 are
indicated by bars above the sequence. Amino acids identical between
BN-1 and either CXCR2 or CCR4 are boxed.
Figure 2. The BN-1 gene maps to chromosome 6. (A) PCR analysis of
hamster, mouse, human and rodent–human hybrid cell line genomic
DNAs (samples 1-20 Biosmap; BIOS Labs., New Haven, CT) using BN-
1–specific primers BN1 and BN2. The lane marked Blank is the result of
PCR in the absence of template, lanes M1 and M2 contain DNA molec-
ular weight markers. The same genomic DNA samples gave positive
PCR signals of the expected size with a second pair of BN-1–specific
PCR primers, BN3 and BN4 (see Materials and Methods). (B) The result
of PCR analysis of the same genomic DNA samples with human TNF-a
promoter primers. The assignment of the BN-1 gene to chromosome 6
was confirmed by PCR analysis of a panel of chromosome 6 deletion and
translocation hybrids (data not shown). PCR analysis of the Genebridge 4
radiation hybrid panel with BN1 and BN2 primers gave the following data
vector: 12202021002210000101200020000000000000000112010000100
0010200011000020210100001020010100000001. The BN-1 data vector
was compared to the WICGR human genome radiation hybrid map
using the Whitehead Institute/Massachusetts Institute of Technology
Center for Genome Research automapper version 1.0 (http//:www-
genome.wi.mit.edu/). The BN-1 STS was placed on chromosome 6,
3.36 centiRay from the framework STS D6S1008 with a lod score .3.0. 
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lines and tissues where limited amounts of mRNA pre-
cluded direct Northern analysis, expression was determined
by the extent of hybridization among the gel-fractionated
population of cDNA inserts from libraries made from those
cells. BN-1 expression was examined first in 19 cDNA li-
braries made from various cells of lymphoid lineage (Fig. 3
 
A
 
, 
 
bottom
 
). BN-1 cDNA was present in one library made
from resting PBMCs, consistent with the observation of
Figure 3. Analysis of BN-1 gene expression. (A) Northern blot analysis
of BN-1 expression in RNA prepared from the various human tissues and
cell lines (top); sizes of RNA markers (in kilobases) are indicated in the left
margin. (Bottom) A Southern blot analysis of BN-1 in cDNA libraries pre-
pared from the human PBL and primary cell T, B, and NK cell cultures.
PBMC, human peripheral blood mononuclear cells; PBMC Act, the same
PBMC stimulated with anti-CD3 and PMA for 2, 6, and 12 h and
pooled; Mot 72 and Mot 81, human Th0 T cell clones. Act, Stimulation
with anti-CD3 and anti-CD28 for 2, 6, and 12 h and pooled; and Anergic,
stimulation with a specific peptide rendering the cells nonresponsive to
antigen stimulation. HY06 and HY93 are human Th1 and Th2 T cell
clones, respectively, with activation and anergy treatments as above ex-
cept for the peptide specificity; B cell pool, a collection of EBV cell lines;
Splen, total human splenocytes, resting; Splen Act, the same population
stimulated with anti-CD40 and IL-4 for 2, 6, and 16 h and pooled; NK
pool, a pool of primary NK cell clones; NK Act 6h, the same pool stimu-
lated 6 h with PMA and ionomycin; NK B1, a single primary human NK
cell clone; NK Act 6h, that clone activated as above. Probing replicate
blots with human b actin cDNA gave readily detectable z2.0-kb species
in all lanes (data not shown). References upon request. (B) Southern blot
of BN-1 distribution (top) in cDNA libraries made from monocytes and
DCs. U937, human monocyte cell line. Human elutriated monocytes
have been stimulated as follows: LPS/IFNg, cultured in the presence of
these activators and blocking antibodies for IL-10 for 1, 2, 6, 12, and 24 h
and pooled; LPS/IFNg/IL10, the same pool without blocking antibodies
to IL-10; LPS 1 h and LPS 6 h, monocytes stimulated for 1 and 6 h with
LPS, respectively; CD34-derived DC, 30 and 70% DCs are CD1a1 DCs
derived from CD341 human cord blood stem cells by growth in GM-CSF
and TNF-a, with the percent CD1a1 cells determined by FACsÒ over
time in culture. The cultures were 70% CD1a1 after 12 d. 70% CD1a1
act 1 h and act 6 h, the same cultured DC stimulated with PMA and iono-
mycin for 1 and 6 h, respectively. Mono-derived DC, DCs derived from
human elutriated monocytes by growth in GM-CSF and IL-4 for 5 and
10 d as listed; GM/IL4/LPS act, 10-d cultures stimulated for 6 h with
LPS; GM/IL4/IL11TNF, are 10-d monocyte-derived DCs stimulated
with IL-1a and TNF-a for 4 and 16 h and pooled. CD34-derived DC,
sorted, DCs derived from CD34 cells as described that were then sorted on
the basis on the cell surface expression of the markers listed: 95% CD1a1,
DC derived from CD1a-sorted cells (Langerhans-like); CD1a1/CD141, DC derived from CD14-sorted cells (dermal/interstitial). (Bottom) The same
blot stripped and reprobed with the human CCF-18/MIP-1g-chemokine. In all cases, the ladder effect represents different sizes of cDNA inserts in the
library ranging from z0.6 to 3.5 kbp for BN-1. The two predominant CCF-18/MIP-1g cDNAS are z0.7 and 1.3 kbp. (C) PCR analysis of unampli-
fied mRNA from DC to confirm BN-1 distribution. Lane 1, CD341 cord blood cells cultured 12 d in GM-CSF and TNF-a; lane 2, CD34-derived
DCs stimulated with PMA and ionomycin; lane 3, CD34-derived DC purified by FACSÒ sorting for 98% CD1a1 expression; lanes 4–8, various cultures
of monocyte-derived DCs (cultured in GM-CSF 1 IL-4 for 8 d) under conditions of stimulation as shown; 1 Ctl, positive control amplification using 1
pg BN-1 plasmid as starting substrate; 2 Ctl, same reaction with identical reagents in the absence of the plasmid substrate. Elutriated monocytes (not
shown) were also negative. Each lane is representative of at least three independent experiments.841 Greaves et al.
Zaballos et al. for expression of the CKR-L3 orphan cDNA
in CD4 and CD8 cells (22), and of the STRL22 orphan in
PBLs (23). Interestingly, however, a matched PBMC library
made after the cells were activated with anti-CD3 antibody
and PMA showed no BN-1 cDNAs, which was further
notable by their absence from virtually every other library
made from T cell lines and clones (in various states of acti-
vation and anergy), pooled B cells, and NK cells (Fig. 3 A,
bottom). Resting human splenocytes contain BN-1 cDNA
(Fig. 3 A, bottom, Splen), but a matched library made after
activation of splenocytes with anti-CD40 and IL-4 (Splen
Act) showed diminished levels of BN-1 cDNA. Thus it ap-
pears that BN-1 may not be abundantly expressed in the
lymphoid lineage, or that its expression is downregulated
with cellular activation or growth in lymphocyte cultures.
Since the original BN-1 PCR product was generated
from a library derived from human DCs, we assessed the
distribution of the receptor among these cells. There are
two principle methods by which DCs can be generated in
vitro: (a) stimulation of peripheral monocyte progenitors
by prolonged exposure of these cells to GM-CSF and IL-4
(24, 25), and (b) by culture of CD341 precursor cells from
bone marrow or cord blood with GM-CSF and TNF. Re-
sultant DCs can be tracked via expression of differentiation
markers such as CD1a and CD86, and purified by sorting
for one or more of these markers. DCs generated by both
procedures take on the typical veiled morphology and
achieve antigen presentation capability (26, 27).
A striking distribution of BN-1 cDNA was seen in a
panel of libraries made from monocytes and two types of in
vitro–derived dendritic cells, suggesting marked differences
between monocyte- and CD34-derived DCs. BN-1 was
not present in any of the libraries derived from purified
elutriated monocytes, and there were few if any BN-1
cDNAs in the libraries prepared from monocyte-derived
DCs (Fig. 3 B, top). By contrast, there is clear expression of
BN-1 as the CD341 cells develop into differentiated DCs
(Fig. 3 B, top). Although little signal is seen when these cul-
tures are 30% CD1a1 (at about day 6), abundant message is
present by the time the cells are 70% CD1a1 (about day
12). Interestingly, when 70% CD1a1 cultures are stimu-
lated for 1–6 h with PMA and ionomycin (70% CD1a1 act
6 h), much less BN-1 cDNA is found in the libraries subse-
quently made from those cells (Fig. 3 B, top). BN-1 is most
abundantly represented in libraries made from DC cultures
derived from cells which were sorted on the basis of CD1a
expression (95% CD1a; Langerhans-like), and less well in
those DCs that were derived from CD141-sorted cells
(dermal/interstitial-like) (Fig. 3 B, top; reference 27). To
control for the quality of monocyte and monocyte-derived
DC libraries, we probed with other markers, including the
CC chemokine human CCF-18/MIP-1g (28). Strikingly,
the cDNA distribution pattern for this chemokine is almost
directly inverse of that for BN-1 (Fig. 3 B, bottom). Finally,
PCR performed directly on primary, unamplified poly A1
mRNA harvested from monocyte- and CD34-derived DCs
yielded amplification products whose pattern mirrored the
hybridizations seen in the library southern blots (Fig. 3 C).
Taken together, the distribution data suggest that BN-1
seems to be expressed most highly in a mature phenotype
of DCs derived from the differentiation of CD341 cells,
and is not well expressed in DCs generated from monocytes.
Figure 4. Chemokine speci-
ficity of the receptor encoded by
BN-1. (A) A sorted population
of transfected CHO cells stably
expressing BN-1 protein con-
taining an NH2-terminal Flag
epitope (CHO-FlagBN-1) show-
ing intensity of anti-Flag mAb
staining relative to wild-type
CHO cells. (B) Panel of purified
recombinant or synthetic che-
mokines assayed for intracellular
calcium mobilizing activity in
various BN-1 transfectants. At
100 nM final concentration 2
indicates no detectable intracel-
lular calcium mobilization in any
of the transfectants (n .3),
whereas  11 denotes a robust
response in all transfectants
(CHO, 3T3, HEK293) bearing
BN-1. (C) Dose response of
MIP-3a in the induction of in-
tracellular calcium in CHO-
FlagBN-1 cells. CHO wild-type
cells are shown as a control. (D)
Binding and homologous com-
petition of radiolabeled MIP-3a
to BN-1–bearing cells. (Inset)
Scatchard transformation of the
binding data to reveal a Kd of
z0.1 nM.842 Chemokine Receptor CCR6 in Dendritic Cells
Chemokine Specificity of the Receptor Encoded by BN-1.
The chemokine literature is replete with cDNA sequences
encoding orphan chemokine receptors of unknown ligand
specificity and unknown function. To assess the ligand-bind-
ing specificity of the putative chemokine receptor encoded
by BN-1, we constructed expression plasmids (pFlagBN-1)
encoding a receptor with an added NH2-terminal Flag
epitope. This allowed for detection and selection of the
most highly expressing stable transfectants using an anti-
Flag monoclonal antibody. To decrease the chance of a
species- or lineage-specific G protein–dependent response,
we also tested BN-1 expression constructs in the following
different types of cells from different species: human embry-
onic kidney 293 (HEK293), murine 3T3 fibroblasts, and chi-
nese hamster ovary (CHO) cells. Stable transfectants were
generated from each of these cell lines; for some, cells were
sorted by anti-Flag antibody for high expression and further
propagation, an example of which is shown in Fig. 4 A.
A panel of purified chemokine ligands was then used to
challenge the various stable transfectants expressing the
BN-1 gene product. Calcium mobilization in the cyto-
plasm of BN-1 transfectants was used to assess receptor en-
gagement and functional coupling to G proteins, as has
been established for other chemokine receptors (21). We
tested a panel of 25 purified recombinant or synthetic
chemokines (listed in Fig. 4 B) including all of the standard
CXC, C, and traditional CC chemokines, as well as the
CX3C chemokine Fractalkine (20). With one exception, all
chemokines were negative for calcium mobilization in re-
combinant BN-1–bearing cells of all backgrounds. One
chemokine, however, the recently described CC chemo-
kine MIP-3a, showed a robust calcium signal, whereas the
wild-type and mock-transfected cells were unresponsive.
MIP-3a exhibited a dose-dependent response, reaching a
plateau at z10 nM (Fig. 4 C). MIP-3a was positive in ev-
ery test on the stable transfectants in all three cellular back-
grounds and also in transfectants expressing the native form
of the receptor (without the NH2-terminal flag), as well as
in a variety of transiently transfected cells of different types
(not shown). We did not detect MIP-3a activity on other
chemokine receptors tested (CCR1–CCR5, and CXCR1
and 2 [not shown]). Competition binding and dissociation
experiments were also performed. Homologous competi-
tion of radioloableled MIP-3a with unlabeled ligand showed
clear dissociation; Scatchard transformation revealed a dis-
sociation constant (Kd) of z0.1 nM (Fig. 4 D). From the
signaling and binding data, we therefore concluded that the
BN-1 gene product is a receptor for the CC chemokine
MIP-3a, hence its designation as CCR6.
Discussion
We report the identification of a cDNA encoding a
chemokine receptor abundantly expressed in certain types
of cultured human DC populations, and the characteriza-
tion of the protein that it encodes. This receptor, desig-
nated here as CCR6, is notable in that of the over two
dozen purified chemokines tested, it appears to interact
only with the newly reported CC chemokine MIP-3a.
CCR6 is expressed most highly in DCs derived from
CD341 cells, but not in monocyte-derived DCs. We have
also noted CCR6 expression in resting PBMCs, consistent
with reports of the presence of transcripts for the orphan
clones CKR-L3 and STRL22 (22, 23). Those reports,
however, did not examine DC populations, nor did they
identify any ligands which bound the orphan cDNA gene
product. The robust but differential patterns of CCR6 sug-
gest that it plays a role in the function of certain types of
DCs. At least three populations of cells with dendritic mor-
phology have been reported in peripheral blood (29, 30).
Each may represent discrete maturational and functional
stages; the possibility has been discussed that the CD34-
derived DCs in vitro are enriched for Langerhans-like cells.
It will be therefore be of interest to assess whether CCR6
will prove to be DC lineage marker in vivo. It is known
that of the different DC populations identified in the pe-
riphery, only one appears to efficiently support HIV-1 in-
fection (30). DCs have been proposed to act in a variety of
sites as a reservoir for HIV-1 (31), although most efficient
infection seems to occur in cocultures of DC and T cells.
The virus can clearly infect DCs alone, and can use the
chemokine receptors CXCR4 and CCR5 as infection co-
factors (18). Additionally, some infection of DC from
CCR5-deficient individuals by M-tropic HIV has been
observed (18), suggesting an additional coreceptor on these
cells. Although we do not yet know how CCR6 expres-
sion relates to the different types of DCs in vivo, it may be
a candidate for an infection cofactor for strains of HIV that
infect DC (32).
It has been shown that monocyte-derived DCs and
CD341 umbilical cord blood–derived DCs are chemotacti-
cally responsive to the CC chemokines RANTES, MIP-
1a, and monocyte chemotactic protein 3 (16, 17). The
chemotactic response of DCs to MIP-3a, however, has not
been reported. Indeed, much remains to be determined as
to the properties of MIP-3a. Recently identified as an or-
phan chemokine of unknown function (19), it has also
been described as LARC (liver activation–related chemo-
kine) by Hieshima et al. (33). Expressed sequence tags con-
taining parts of the MIP-3a–coding region were generated
from sequence analysis of fetal lung, liver, and pancreatic is-
let cDNA libraries (19, 33). Although a CC chemokine,
MIP-3a is widely diverged from other CC chemokines,
showing only 20–28% identity with other members of the
CC family and being encoded on chromosome 2 rather
than chromosome 17 (33). The chemotactic properties of
MIP-3a, especially as mediated through CCR6, are cur-
rently being studied. LARC protein was shown to induce
chemotaxis of T cells, albeit less potently and efficiently
than RANTES (33). This would be consistent with CCR6
expression in T cells as noted here and for CKR-L3 (22),
but the existence of other MIP-3a receptors on lympho-
cytes cannot be excluded. Our experiments suggest that
levels of CCR6 expression in other cells are low relative to843 Greaves et al.
the levels seen in DCs, and it is notable that CCR6 so far
exhibits specificity only for MIP-3a among the extensive
panel of chemokines tested. The specificity of CCR6 bind-
ing is supported by the evidence of Baba et al., whose study
appeared while the present manuscript was under revision,
reporting a receptor of identical sequence, GPR-CY4, that
binds specifically to LARC/MIP-3a (34). Again, that study
did not examine dendritic cell distribution or function.
In summary, the identification of CCR6 as a provision-
ally specific receptor for the CC chemokine MIP-3a defines
another piece in the puzzle of chemokine–chemokine recep-
tor interactions. Detailed analysis of CCR6 and its CC
chemokine ligand may shed new light on the control of DC
migration and function, providing a potential therapeutic
avenue for treatment of a wide range of pathologies including
HIV infection, autoimmunity, and transplant rejection.
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